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Several studies have shown that elevated plasma levels of
coagulation factor VIII (FVIII) are a risk factor of venous
thrombosis. This risk remained after correction for the main
determinants of FVIII levels, blood group and vonWillebrand
factor (VWF) [1–3]. FVIII activity levels (FVIII:C)
‡150 IU dL)1 increase the risk of a ﬁrst venous thrombosis
ﬁvefold when compared to levels >100 IU dL)1. The preval-
ence of FVIII:C ‡ 150 IU dL)1 among thrombosis patients is
25%. Since these levels are found in 10% of the population, the
contribution of elevated FVIII levels to all thrombotic events in
the population is considerable [2]. Several lines of evidence
support the idea that high FVIII levels are indeed causative to
thrombosis and not a consequence of the thrombotic event,
such as a dose-dependent relationship with risk [2], the
persistence of elevated levels over time [3] and familial
clustering [4]. The last of these, familial clustering, supports
the hypothesis that FVIII levels are, at least in part, determined
genetically. Because no variations have been found in the FVIII
and VWF genes that are associated with thrombosis [1,5], it is
likely that genes encoding proteins regulating plasma levels of
FVIII and VWF are involved.
A candidate regulator of FVIII levels is the b2-adrenergic
receptor (b2AR). It is well-known that epinephrine infusion
causes a signiﬁcant rise in FVIII levels. This effect can be
blunted by prior administration of a b-blocker. Hoppener et al.
[6] showed that in patients with venous thromboembolism and
FVIII levels >175 IU dL)1, FVIII:C levels could be effect-
ively lowered by treatment with propranolol. FVIII:C returned
to its initial elevated levels within 2 months after discontinu-
ation of treatment. However, Scho¨nauer et al. [7] reported that
in patients with venous thromboembolism and FVIII levels
>170 IU dL)1, propranolol administration could not lower
FVIII levels signiﬁcantly. We approached this issue from a
different angle by determining the possible association of single
nucleotide polymorphisms (SNP) in the b2AR gene with FVIII
and VWF levels and thrombotic risk.
We studied three coding b2AR SNPs, that have previously
been implicated in clinically relevant effects [8–10], in a large
population-based, case–control study, the Leiden Thrombo-
philia Study (LETS). The LETS consists of 474 consecutive
patients and 474 controls. All the patients were referred for
anticoagulant treatment after a ﬁrst objectively conﬁrmed
episode of deep vein thrombosis. Patients with underlying
malignancies were excluded. The controls were matched for
sex and age. DNA samples are available for 469 cases and
470 controls. FVIII:C was measured in the plasma of all
these participants by a one-stage clotting assay. VWF antigen
and FVIII antigen (FVIII:Ag) were measured by enzyme-
linked immunosorbent assay in the plasma of 301 patients
and 301 controls. The design of this study has previously
been described in more detail [11]. Using polymerase chain
reaction–restriction fragment length polymorphism analyses
the three b2AR SNPs, Arg16Gly, Glu27Gln and Thr164Ile,
were determined.
The distributions of genotypes for the three SNPs studied
were inHardy–Weinberg equilibrium in the controls. The allele
frequencies in the controls were consistent with those found in
previous studies [12,13]. No differences in allelic distributions
were observed between the cases and controls (Table 1). There
was a protective effect on the occurrence of venous thrombosis
for the rare allele of Thr164Ile, however, this effect was weak,
with wide conﬁdence limits around the odds ratio. Based on the
frequencies of the SNPs, four different haplotypes were
identiﬁed in our study population (Table 1) with the help of
special software, ARLEQUIN [14]. These haplotypes correspon-
ded to those reported in previous publications [10,12]. No
signiﬁcant differences were found in the distribution of the
haplotypes between cases and controls. The trend we observed
for the rare allele of Thr164Ile was recovered in haplotype 4. In
addition, homozygotes for haplotype 2 showed an odds ratio of
1.67 (95% conﬁdence interval: 0.75–3.74). Combining this with
the results for the individual SNPs, it is unlikely that the gene
for the b2AR contains a common polymorphism that is
associated with the risk of venous thrombosis.
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No association was found between FVIII:C, FVIII:Ag and
VWF levels and the different genotypes and haplotypes in the
control group. Because ABO blood group strongly inﬂuences
levels of FVIII and VWF, we also analyzed the data stratiﬁed
by blood group O and non-O in healthy individuals. Again, no
effect was observed.
O’Donnell et al. [13] recently reported a signiﬁcant effect on
FVIII:C levels for SNP Glu27Gln in healthy blood group O
individuals. They found, that in a group of 59 healthy blood
group O individuals, those with genotype Gln/Gln had lower
levels of FVIII:C than those with genotype Glu/Glu. However,
this effect was very small and only marginally signiﬁcant. In
our study, we could not conﬁrm these results in a group of 201
healthy blood group O individuals. FVIII:C levels within this
group were for Gln/Gln: 111.04 IU dL)1 (104.14–117.95), for
Gln/Glu: 109.01 IU dL)1 (102.18–115.84) and for Glu/Glu:
109.54 IU dL)1 (99.50–119.57).
In conclusion, genotypes and haplotypes of the b2AR have
no inﬂuence on either the occurrence of venous thrombosis or
the plasma levels of FVIII and VWF. It remains to be
determined what genetic variations are responsible for the
familial clustering of elevated levels of FVIII.
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Fibrinogen is a 340 kDa major glycoprotein found in plasma
that is central to the blood clotting process [1]. It is synthesized
primarily in hepatocytes and secreted as a hexamer composed
of three pairs of polypeptide chains, Aa, Bb and c [2]. Three
chains are encoded by different genes (FGA, FGB and FGG,
respectively) clustered in a region of approximately 50 kilo-
bases on chromosome 4q28 [3]. During blood coagulation,
thrombin converts ﬁbrinogen to ﬁbrin monomers, which
associate into staggered overlapping two-stranded ﬁbrils. These
then associate laterally to form ﬁbrin bundles [4]. In the ﬁnal
step, these bundles cross-link with each other by formation of
covalent intermolecular isopeptide bonds to form a three-
dimensional network. This reaction is catalyzed by factor
XIIIa, which links the a and c chains of two adjacent ﬁbrin
molecules in the presence of Ca2+ [5,6]. Cell-derived tissue
transglutaminase can also cross-link ﬁbrin bundles, but it does
so by cross-linking two a chains [7].
In addition to end-stage coagulation reactions, ﬁbrinogen
also participates in early stages of hemostasis by promoting
platelet aggregation [1]. Apart from its role in hemostasis, the
ﬁbrin network formed provides a temporary matrix for cell
invasion during the subsequent healing process [8,9]. Thus, the
clinical manifestations of qualitative or quantitative deﬁciency
ofﬁbrinogenmanifest bothwithhemostasis andhealingdefects.
Congenital aﬁbrinogenemia (MIM 202400) is a rare auto-
somal recessive disorder described for the ﬁrst time in 1920 [10]
and is characterized by unmeasurable clottable and extremely
low antigen levels in plasma [11]. Diagnosis is often made at
birth because of bleeding from the umbilical stump. Some
150 families with about 250 cases of congenital aﬁbrinogenemia
have been reported so far [12,13]. We report here three more
cases of congenital aﬁbrinogenemia from three different
families.
One female and two male infants, aged 2, 3 and 5 months,
respectively, presented with uncontrolled bleeding from the
umbilical stump and hematoma formation at intramuscular
(vitamin K) injection sites. They were all products of ﬁrst-
cousin marriages and had been born at full term by normal,
vaginal delivery. The number of siblings varied from one to
three. There was no family history of bleeding tendency in any
of the families.
On examination, no abnormality was detected except for
oozing from the umbilical stump and hematomas at injection
sites. Blood counts and liver function tests were normal in all
infants. However, prothrombin time (PT), partial thrombo-
plastin time with kaolin (PTTK) and thrombin time (TT) were
inﬁnitely prolonged in all three patients but were normal in
their parents. Fibrin degradation products were not detected in
any of the patients. Fibrinogen was undetectable in plasma by
the Clauss method. There was no band in the normal
ﬁbrinogen position on plasma protein electrophoresis on
cellulose acetate membrane. Immunoreactive ﬁbrinogen could
not be determined because of a lack of facilities. Details are
shown in Table 1. All three patients responded to ﬁbrinogen
replacement therapy with cryoprecipitate and were prescribed
life-long replacement therapy with ﬁbrinogen concentrates.
Congenital ﬁbrinogen disorders include aﬁbrinogenemia,
hypoﬁbrinogenemia and dysﬁbrinogenemia, which are charac-
terized by the complete absence or extremely low levels of
plasma ﬁbrinogen, by reduced amounts of plasma ﬁbrinogen,
or by the presence of dysfunctional ﬁbrinogen molecules,
respectively [11]. Of these, congenital aﬁbrinogenemia is the
rarest and has a high rate in consanguineous families [11], as
was the case for the parents of the infants described above. It
most commonly presents at birth with abnormal bleeding from
the umbilical stump [11], as seen in the three patients described
in this report. Other clinical manifestations include bruises,
hemarthrosis and gastrointestinal bleeding. The major cause of
death is intracranial hemorrhage during infancy or childhood
[14]. Only about 250 patients have been reported so far, mostly
from Europe and North America [11,15]. From the Indo-
Pakistan subcontinent, only three cases have been described
previously, two families from Pakistan and one from India
[16,17]. We are reporting three more families with one patient
in each from Pakistan.
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